
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion is a promising healthcare technology company with a strong proprietary technology and a growing customer base, as reflected in its solid Q1 FY26 revenue and EPS beats. While increased operating expenses could potentially affect its bottom line, the recent addition of new commercial agreements and a senior hire demonstrate a strong marketing push. With a growing patent portfolio, ongoing clinical trials, and a healthy balance sheet, Aclarion appears well-positioned for long-term success in the healthcare market.
Bears say
Aclarion is undergoing a CLARITY trial in Q4 2026 to provide supportive data for Nociscan's efficacy in improving surgical outcomes for chronic low back pain. However, the company's revenue sources are limited to one product and are solely based on contracts in the US, which poses a substantial risk for financial stability. With the interim data expected in 2026, the company's future financial performance and success will be heavily dependent on the success of the trial and market adoption of Nociscan.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares